



For immediate release

Seinäjoki, Finland 14.4.2022

Eevia Health appoints a Shareholders' Nomination Committee

Eevia Health Plc, ("Eevia" or "The Company") has appointed a Shareholders' Nomination Committee

The following members have been appointed to Eevia's Shareholders' Nomination Committee: Joel Westerström, Partner at Partner Fondkommission AB; Tuomas Lehtimäki, Partner at Smartius Law Firm; Martin Bjørklund, Chairman of the Company's Board of Directors.

The nomination is in line with a decision taken by the Annual General Meeting (AGM) held on 22 June 2021. However, the process of establishing the Nomination Committee has taken longer than originally anticipated. As such, in order to be pragmatic during this first year, the board has decided to simplify the committee for the current period. As such, we have limited the number of members to three. We anticipate increasing the number of members to four next year.

The Nomination Committee is responsible for drafting and presenting proposals covering the remuneration and number of members of the Board of Directors and for presenting candidates as potential Board members to the AGM. The Nomination Committee will forward its proposals for the AGM to the Board of Directors in time for them to be included in the invitation to the meeting sent out to shareholders.

Eevia Health Plc
Gabriella Beni
CFO

For further information, please contact:

Martin Bjørklund, Eevia Health Plc
Chair of the Board of Directors
Telephone: +47 48 40 51 97



INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, Chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name [EEVIA](#).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.



ANNEX 1

CHARTER FOR THE SHAREHOLDERS' NOMINATION COMMITTEE

1. Role and duties of the Nomination Committee

1.1. The Nomination Committee shall be responsible for preparing and drawing up proposals covering remuneration and number of members of the Board of Directors, and a list of proposed Board members for presentation to the AGM and to an Extraordinary General Meeting of Shareholders, if applicable. The Nomination Committee shall also be responsible for identifying candidates as potential successors to existing members of the Board of Directors.

1.2. The Nomination Committee shall act in accordance with the resolutions of the General Meeting, the law, and the stock exchange regulations applicable to the Company.

2. Composition of the Nomination Committee

2.1. The Nomination Committee shall consist of four (4) members, three of which shall be appointed by the Company's three largest shareholders, who shall appoint one member each. The Chairman of the Company's Board of Directors shall serve as the fourth member.

2.2. The Company's largest shareholders entitled to elect members to the Nomination Committee shall be determined annually on the basis of the registered holdings in the Company's list of shareholders as of the first weekday in September in the year concerned.

2.3. The Chairman of the Company's Board of Directors shall request each of the three largest shareholders established on this basis to nominate one member to the Nomination Committee. In the event that a shareholder does not wish to exercise his or her right to appoint a representative, it shall pass to the next largest shareholder who would not otherwise be entitled to appoint a member to the Nomination Committee.

2.4. The Chairman of the Board of Directors shall convene the first meeting of the Nomination Committee, which will be responsible for electing a Chairman from among its members; the Nomination Committee's Chairman shall be responsible for convening subsequent meetings. The Company will issue a release when the Nomination Committee has been appointed.

2.5. The Nomination Committee shall serve until further notice until the AGM decides otherwise. Its members shall be elected annually and their term of office shall end when new members are elected to replace them.

2.6. Shareholders shall be entitled to replace the members that they have elected during the latter's term of office, should they so wish, by informing the Chairman of the Nomination Committee.



2.7. The members of the Nomination Committee shall be independent of the Company, and a person belonging to the Company's senior management cannot serve as a member of the Nomination Committee.

2.8. The members of the Nomination Committee shall not be entitled to any remuneration from the Company on the basis of their membership. The traveling costs of members shall be reimbursed in accordance with the Company's travel policy. In carrying out its duties, the Nomination Committee can make use of outside experts, at the Company's expense, and with its approval, to identify and evaluate potential new candidate members for the Board of Directors.

3. Proposals put before the AGM

3.1. The Nomination Committee shall forward its proposals for the AGM, or an Extraordinary General Meeting if applicable, to the Company's Board of Directors in time for them to be included in the invitation to the meeting sent out to shareholders, prior to the holding of said General Meeting.

3.2. Candidates proposed as members of the Board of Directors shall be suitably qualified and be able to devote sufficient time to carrying out their duties.

3.3. The Nomination Committee shall agree unanimously on the proposals to be put before the AGM. Should it prove impossible to reach unanimous agreement, the Nomination Committee shall inform the Company's Board of Directors that it is unable to make a proposal for the AGM.

4. Confidentiality

4.1. The Nomination Committee shall keep its proposals intended for the AGM confidential until they have been published by the Company. Members of the Nomination Committee shall attend to the confidentiality of all Company information that they receive.

4.2. The regulations of the Market Abuse Regulation (MAR) and other relevant legislation shall be applied to any insider information that the Nomination Committee might receive.